Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program

Excerpt:

“Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment.

“Rucaparib is an oral inhibitor of poly ADP-ribose polymerase (PARP), approved in the U.S. in 2016 as Rubraca™ (rucaparib) as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic. Emerging data suggest PARP inhibition may also provide activity in the treatment of metastatic prostate cancers harboring deleterious mutations in BRCA1/2 and ATM or other human genes associated with DNA damage repair. These mutations may be germline (inherited) or somatic (acquired).”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Obesity Biomarkers and Prostate Cancer Study Suggests Obesity Can Accelerate Prostate Cancer Progression

A study of 500 men finds that higher body mass index, leptin blood levels, and waist-hip ratio were significantly associated with higher grade prostate cancer and suggests detection bias during prostate biopsy has resulted in
inconsistent results when the association between obesity and prostate cancer was previously studied.


A Plea for Surgical Lymph Node Staging in Advanced Prostate Cancer from European Oncologists

Clinicians advocate for a prostate cancer treatment via pelvic lymph node irradiation strategy for high-risk prostate cancer patients to be based on surgical staging. New techniques of gamma-camera-navigated surgery and fluorescence guidance to the sentinel node could improve the staging.


Targeting Constitutively Activated β1 Integrin Could Be a New Target for Prevention of Metastasis of Prostate Cancer

Researchers from the MD Anderson Cancer Center in Houston show that β1 integrin activation occurs in metastatic progression of prostate cancer and is constitutively active in late state prostate cancer cells. The study shows the integrin palys a reole in survival of metastatic prostate cancer cells in circulation. Inhibition of β1 integrin activity by antibody or knockdown results in increased apoptosis.


Prostate cancer risk reduction in men taking dutasteride, but some concerns remain

Nearly 2,800 men participated in the four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) observational clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7).


Consistent epigenetic ‘signatures’ found in prostate cancer patients’ metastatic tumors

Researchers at Johns Hopkins analyzed 13 metastatic prostate tumors, finding a a consistent epigenetic signature among the samples. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity.


Baldness by age 40 linked to prostate cancer, retrospective Australian study shows

University of Melbourne reserachers analyzed 9.448 men from the Melbourne Collaborative Cohort Study (MCCS), a prospective cohort study that was set up to investigate the role of diet and life style factors in chronic diseases including prostate, breast and bowel cancers, for hair patterns. After a more than 11 year follow-up, researchers found vertex androgenetic alopecia at age 40 years was associated with earlier age at onset of prostate cancer, and increased cumulative probability of prostate cancer up to age 76 years.


In UK, Prostate Cancer Diagnoses Increase as Deaths Decrease

1 in 7 boys born in 2015 will be diagnosed with prostate cancer compared to 1 in 20 in 1990 according to a Cancer Research UK study. The good news is deaths from prostate cancer have dropped off by 18% in the last 20 years. The lifetime risk of being diagnosed with prostate cancer is going from 5% (a 1 in 20 chance) for men born in 1990 to 14% (a 1 in 7 chance) to those born in 2015 according to data from the Cancer Research UK. On the positive side, deaths from prostate cancer are 18% lower than 20 years ago.


Cabozantinib Improves PFS in for Castrate-Resistant Prostate Cancer in Phase II Trial

171 patient trial shows median PFS of 23.9 weeks with cabozantinib and 5.9 weeks with placebo. 72% of patients had regression in soft tissue lesions, whereas 68% of evaluable patients had improvement on bone scan, including complete resolution in 12%.